For patients and families living with metastatic uveal melanoma, treatment options remain limited, making every new research development especially important. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Immatics presented updated data on anzu-cel (anzutresgene autoleucel), an investigational PRAME-directed T-cell therapy that continues to generate excitement within the melanoma community.
The study evaluated patients with advanced melanoma who had already undergone previous treatments. Among the 33 participants treated with anzu-cel at the recommended Phase 2 dose, 16 had metastatic uveal melanoma. These patients had Stage IV disease, including liver and extrahepatic metastases, representing a group with significant unmet medical needs.
One of the most encouraging findings was the level of tumor response observed in patients with uveal melanoma. Researchers reported an overall response rate of 69%, meaning that more than two-thirds of patients experienced measurable tumor shrinkage. Additionally, the disease control rate was 88%, suggesting that most patients either responded to treatment or maintained stable disease.
Beyond response rates, the durability of those responses is what stands out. The study showed that responses occurred quickly, with a median time to best response of just 1.4 months. Some patients experienced long-lasting benefits, and several responses remained ongoing for years after treatment. Researchers also noted that many tumors continued to remain controlled even when new lesions appeared elsewhere, suggesting persistent anti-tumor activity throughout the body.
Another positive aspect of the study was safety. The side effects observed were generally predictable and manageable. Most cytokine release syndrome events were mild, and serious neurological side effects were uncommon. These findings are particularly important because cellular therapies can sometimes be associated with significant toxicities.
Anzu-cel works by targeting PRAME, a protein commonly found on melanoma cells and many other cancers. The therapy uses a patient’s own immune cells, which are engineered to recognize and attack PRAME-expressing cancer cells. This personalized approach represents a growing area of cancer treatment known as T-cell receptor (TCR) therapy.
While anzu-cel remains investigational and is not yet approved by the FDA, these latest results offer meaningful hope for the uveal melanoma community. Immatics continues to enroll patients in an ongoing Phase 2 cohort for metastatic uveal melanoma while advancing its Phase 3 SUPRAME trial in cutaneous melanoma. If future studies confirm these results, anzu-cel could become an important new treatment option for patients facing advanced uveal melanoma.
For families affected by ocular melanoma, this research represents another encouraging step toward more personalized and effective therapies that may improve outcomes in the years ahead.